SG194701A1 - Anti-cd40 antibodies and methods of use - Google Patents
Anti-cd40 antibodies and methods of use Download PDFInfo
- Publication number
- SG194701A1 SG194701A1 SG2013080452A SG2013080452A SG194701A1 SG 194701 A1 SG194701 A1 SG 194701A1 SG 2013080452 A SG2013080452 A SG 2013080452A SG 2013080452 A SG2013080452 A SG 2013080452A SG 194701 A1 SG194701 A1 SG 194701A1
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- antibodies
- cancer
- diseases
- variety
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480863P | 2011-04-29 | 2011-04-29 | |
| US201261622435P | 2012-04-10 | 2012-04-10 | |
| PCT/US2012/035502 WO2012149356A2 (en) | 2011-04-29 | 2012-04-27 | Anti-cd40 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG194701A1 true SG194701A1 (en) | 2013-12-30 |
Family
ID=47073090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013080452A SG194701A1 (en) | 2011-04-29 | 2012-04-27 | Anti-cd40 antibodies and methods of use |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US8778345B2 (enExample) |
| EP (2) | EP2702078B1 (enExample) |
| JP (3) | JP6125489B2 (enExample) |
| KR (2) | KR20190122889A (enExample) |
| CN (3) | CN103635488B (enExample) |
| AU (1) | AU2012249454B2 (enExample) |
| BR (1) | BR112013027829B1 (enExample) |
| CA (1) | CA2834404C (enExample) |
| ES (1) | ES2709654T3 (enExample) |
| IL (1) | IL229098A0 (enExample) |
| MX (1) | MX339239B (enExample) |
| RU (1) | RU2609647C2 (enExample) |
| SG (1) | SG194701A1 (enExample) |
| WO (1) | WO2012149356A2 (enExample) |
| ZA (1) | ZA201308022B (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| CN102002104A (zh) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| RS60612B1 (sr) | 2010-03-31 | 2020-08-31 | Boehringer Ingelheim Int | Anti-cd40 antitela |
| US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| CN103635488B (zh) * | 2011-04-29 | 2016-12-14 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| EP2914627B1 (en) | 2012-10-30 | 2021-04-07 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| EP2951209A4 (en) | 2013-01-31 | 2016-06-22 | Univ Jefferson | CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF |
| WO2014144725A2 (en) * | 2013-03-15 | 2014-09-18 | Salimetrics, Llc | Melatonin monoclonal antibody, detection, methods and uses thereof |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| CN104892753B (zh) * | 2014-03-07 | 2019-11-29 | 神州细胞工程有限公司 | 一种中和人感染h7n9甲型流感病毒的抗体及其用途 |
| WO2015200697A1 (en) | 2014-06-25 | 2015-12-30 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| UY36692A (es) | 2015-05-29 | 2016-12-30 | Abbvie Inc | Anticuerpos anti-cd40 y usos de los mismos |
| CA2986705A1 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | A cxcr4 inhibitor and a pdi antagonist for use in treating cancer |
| BR112018001907A2 (pt) * | 2015-09-01 | 2018-09-25 | Boehringer Ingelheim Int | uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica |
| MX2018003905A (es) | 2015-09-30 | 2018-09-06 | Janssen Biotech Inc | Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso. |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| EA039944B1 (ru) * | 2016-01-27 | 2022-03-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Применение антител к cd40 для лечения волчаночного нефрита |
| WO2017156349A1 (en) | 2016-03-10 | 2017-09-14 | Cold Genesys, Inc. | Methods of treating solid or lymphatic tumors by combination therapy |
| CN109689694B (zh) | 2016-05-19 | 2022-11-22 | 通用医疗公司 | 与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台 |
| CA3025345A1 (en) | 2016-05-27 | 2017-11-30 | Abbvie Biotherapeutics Inc. | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
| SG10201914132RA (en) | 2016-05-27 | 2020-03-30 | Abbvie Biotherapeutics Inc | Anti-cd40 antibodies and their uses |
| DK3468997T5 (da) | 2016-06-08 | 2024-09-09 | Xencor Inc | Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| US10501775B2 (en) | 2016-07-12 | 2019-12-10 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
| UA128304C2 (uk) | 2016-07-14 | 2024-06-05 | Ґенмаб А/С | Мультиспецифічне антитіло до cd40 і cd137 |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| PL3518972T3 (pl) * | 2016-09-28 | 2025-04-07 | Kite Pharma, Inc. | Cząsteczki wiążące antygen i sposoby ich zastosowania |
| AU2017353852A1 (en) * | 2016-11-02 | 2019-05-23 | Apexigen, Inc. | Anti-CD40 antibodies in combination and methods of use |
| WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
| BR112019018759A2 (pt) | 2017-05-30 | 2020-05-05 | Bristol-Myers Squibb Company | composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico |
| CN110267989B (zh) | 2017-06-01 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及其医药用途 |
| CN109384845B (zh) * | 2017-08-14 | 2022-06-21 | 中国科学院上海营养与健康研究所 | 一种cd40单克隆抗体、其制备方法及其应用 |
| IL272770B2 (en) * | 2017-09-19 | 2025-08-01 | Mab Discovery Gmbh | Agonistic cd40 antibodies |
| US10844371B2 (en) * | 2017-09-22 | 2020-11-24 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
| RU2020117156A (ru) * | 2017-12-01 | 2022-01-04 | Эббви Инк. | Конъюгаты анти-cd40 антитела и лекарственного средства |
| EP3732196A4 (en) | 2017-12-28 | 2022-01-05 | Astute Medical, Inc. | ANTIBODIES AND ASSAYS FOR CCL14 |
| US11078283B2 (en) | 2018-01-17 | 2021-08-03 | Apexigen, Inc. | Anti-PD-L1 antibodies and methods of use |
| JP2021512956A (ja) | 2018-02-06 | 2021-05-20 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍免疫応答のバイオマーカーとしてのリピートｒｎａ |
| CN108671958B (zh) * | 2018-06-06 | 2020-11-06 | 青岛科技大学 | 双离子二维有机多孔材料及其制备方法 |
| EP3807320A4 (en) * | 2018-06-12 | 2022-03-23 | BioNTech US Inc. | POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| EP3820885A4 (en) | 2018-07-11 | 2022-04-20 | The Brigham & Women's Hospital, Inc. | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF DRUGS ACROSS THE BLOOD-BRAIN BARRIER |
| MX2021000688A (es) | 2018-07-20 | 2021-03-25 | Eucure Beijing Biopharma Co Ltd | Anticuerpos anti-cd40 y usos de los mismos. |
| AR117091A1 (es) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| CN112839961B (zh) | 2018-11-30 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 一种cd40抗体药物组合物及其用途 |
| JP2022509156A (ja) * | 2018-11-30 | 2022-01-20 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 |
| CN111548415B (zh) * | 2019-03-04 | 2021-04-20 | 北京天广实生物技术股份有限公司 | 与cd40特异结合的抗体及其用途 |
| WO2020193718A1 (en) | 2019-03-27 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Recombinant proteins with cd40 activating properties |
| EP3947640A4 (en) | 2019-04-02 | 2022-12-14 | The Brigham & Women's Hospital, Inc. | PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA |
| CA3136491A1 (en) | 2019-04-10 | 2020-10-15 | Nankai University | Anti-cd40 antibodies and uses thereof |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| AU2020300544B2 (en) * | 2019-07-02 | 2024-07-25 | Astute Medical, Inc | Antibodies and assays for CCL14 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| AU2021206256A1 (en) | 2020-01-10 | 2022-07-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer |
| KR20230020521A (ko) * | 2020-06-04 | 2023-02-10 | 셀벡스 피티와이 리미티드 | 아고니스트 항-cd40 항체 |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| JP2023538105A (ja) * | 2020-08-21 | 2023-09-06 | ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド | Ｃｄ４０アゴニスト抗体及び使用方法 |
| WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| CN115768477A (zh) * | 2021-06-29 | 2023-03-07 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别cd40的抗体及其应用 |
| KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| US20240343817A1 (en) * | 2021-07-14 | 2024-10-17 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibody that specifically recognizes cd40 and application thereof |
| CN120463762A (zh) | 2021-08-26 | 2025-08-12 | 映恩生物科技(上海)有限公司 | 一种甾体化合物及其缀合物 |
| CN116410326A (zh) | 2021-12-30 | 2023-07-11 | 三优生物医药(上海)有限公司 | 抗cd40×cldn18.2双特异性抗体及其用途 |
| US20250099588A1 (en) | 2022-01-28 | 2025-03-27 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| CN115845063B (zh) * | 2022-12-20 | 2024-07-09 | 中国医学科学院医学生物学研究所 | 与急性t淋巴细胞白血病治疗相关的靶点cd40lg及其应用 |
| TW202430226A (zh) * | 2022-12-28 | 2024-08-01 | 大陸商上海盛迪醫藥有限公司 | 抗cd40抗體藥物偶聯物、其製備方法及其醫藥用途 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN119569860B (zh) * | 2023-09-07 | 2025-11-18 | 菲鹏生物股份有限公司 | 一种抗p24抗体及其应用 |
| WO2025085799A1 (en) * | 2023-10-19 | 2025-04-24 | Adverum Biotechnologies, Inc. | Anti-aav2.7m8 antibodies and methods of use thereof |
| WO2025235683A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Methods and compositions for prevention of transplant rejection |
| WO2025235670A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5247069A (en) | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| JP3675819B2 (ja) | 1993-10-01 | 2005-07-27 | イミュネックス・コーポレーション | Ｃｄ４０に対する抗体 |
| DE69433820T2 (de) | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
| US5675063A (en) | 1995-02-28 | 1997-10-07 | Loyola University Of Chicago | Immortalized rabbit hybridoma fusion partner |
| NZ305083A (en) | 1995-03-01 | 1999-06-29 | Immunex Corp | Use of cd40 binding proteins (a cd40 ligand or monoclonal antibody that specifically binds to cd40) for stimulating a immune response |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6680176B2 (en) | 1999-05-17 | 2004-01-20 | The United States Of America, As Represented By The Department Of Health And Human Services | Identification of candidate ligands which modulate antigen presenting cells |
| US20030118588A1 (en) | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| BR0108001A (pt) | 2000-02-01 | 2004-01-06 | Tanox Inc | Moléculas ativadoras de apc com ligação para cd-40 |
| CA2406961A1 (en) | 2000-04-19 | 2002-02-14 | Tanox, Inc. | Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| KR100643818B1 (ko) | 2000-05-08 | 2006-11-10 | 셀덱스 쎄라퓨틱스, 인크. | 수상세포에 대한 인간 모노클로날 항체 |
| JP4025881B2 (ja) | 2001-04-27 | 2007-12-26 | キリンファーマ株式会社 | 抗ｃｄ４０モノクローナル抗体 |
| EP2009027B1 (en) * | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| RU2377254C2 (ru) | 2003-12-25 | 2009-12-27 | Кирин Фарма Кабусики Кайся | Мутанты анти-cd40 антитела |
| BRPI0514068B8 (pt) | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| CA2595682A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| JP5421590B2 (ja) | 2005-05-18 | 2014-02-19 | ノバルティス アーゲー | 自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法 |
| WO2006125143A2 (en) | 2005-05-18 | 2006-11-23 | Novartis Ag | Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling |
| ATE485057T1 (de) | 2005-05-26 | 2010-11-15 | Seattle Genetics Inc | Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung |
| US7429487B2 (en) | 2005-07-05 | 2008-09-30 | Epitomics, Inc. | Fusion partner for production of monoclonal rabbit antibodies |
| AU2006308606C1 (en) | 2005-11-01 | 2013-07-25 | Novartis Ag | Uses of anti-CD40 antibodies |
| RU2442606C2 (ru) | 2005-11-01 | 2012-02-20 | Новартис Аг | Применение анти-cd40-антител |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| MX2008007140A (es) | 2005-12-09 | 2009-03-04 | Seattle Genetics Inc | Metodos para utilizar agentes de union a cd40. |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CN103172743B (zh) * | 2006-12-01 | 2015-04-08 | 梅达雷克斯有限责任公司 | 结合cd22的人抗体及其用途 |
| CN101605906A (zh) * | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US20090238825A1 (en) | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| MX343879B (es) | 2007-05-21 | 2016-11-25 | Alderbio Holdings Llc | Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados. |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| EP3392273A1 (en) | 2007-05-30 | 2018-10-24 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| AU2009206506B2 (en) * | 2008-01-23 | 2013-01-10 | Xencor, Inc. | Optimized CD40 antibodies and methods of using the same |
| ES2685823T3 (es) * | 2008-07-16 | 2018-10-11 | Baylor Research Institute | Anticuerpos antagonistas anti-CD40 |
| CN102105959B (zh) * | 2008-07-30 | 2014-11-26 | Abb研究有限公司 | 具有光纤电流传感器的发电机断路器 |
| AU2009286247A1 (en) | 2008-08-29 | 2010-03-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Delivery of a CD40 agonist to a tumor draining lymph node of a subject |
| ES2650267T3 (es) | 2008-12-05 | 2018-01-17 | Als Therapy Development Institute | Método para el tratamiento de enfermedades neurodegenerativas |
| EP2406286B1 (en) | 2009-03-10 | 2016-05-18 | Baylor Research Institute | Anti-cd40 antibodies and uses thereof |
| US9617600B2 (en) | 2009-04-18 | 2017-04-11 | Genentech, Inc. | Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
| JP5694921B2 (ja) * | 2009-04-20 | 2015-04-01 | 協和発酵キリン株式会社 | アミノ酸変異が導入されたＩｇＧ２を有する抗体 |
| RU2012145183A (ru) | 2010-03-29 | 2014-05-10 | Займворкс, Инк. | Антитела с повышенной или пониженной эффекторной функцией |
| RS60612B1 (sr) | 2010-03-31 | 2020-08-31 | Boehringer Ingelheim Int | Anti-cd40 antitela |
| US10131875B2 (en) | 2010-08-04 | 2018-11-20 | Duke University | Regulatory B cells and their uses |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| CA3167037A1 (en) | 2010-12-20 | 2012-06-28 | The Rockefeller University | Modulating agonistic tnfr antibodies |
| US9475879B2 (en) | 2011-04-21 | 2016-10-25 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
| CN103635488B (zh) | 2011-04-29 | 2016-12-14 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| EP2914627B1 (en) | 2012-10-30 | 2021-04-07 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| EP3552665A3 (en) | 2014-08-12 | 2019-12-18 | Alligator Bioscience AB | Antibodies |
| BR112017011538A2 (pt) | 2014-12-04 | 2018-03-13 | Bristol-Myers Squibb Company | combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma) |
| AU2017353852A1 (en) | 2016-11-02 | 2019-05-23 | Apexigen, Inc. | Anti-CD40 antibodies in combination and methods of use |
-
2012
- 2012-04-27 CN CN201280031910.5A patent/CN103635488B/zh active Active
- 2012-04-27 CN CN202110743353.0A patent/CN113461819B/zh active Active
- 2012-04-27 US US13/458,730 patent/US8778345B2/en active Active
- 2012-04-27 KR KR1020197031186A patent/KR20190122889A/ko not_active Ceased
- 2012-04-27 RU RU2013152960A patent/RU2609647C2/ru active
- 2012-04-27 CA CA2834404A patent/CA2834404C/en active Active
- 2012-04-27 BR BR112013027829-3A patent/BR112013027829B1/pt active IP Right Grant
- 2012-04-27 SG SG2013080452A patent/SG194701A1/en unknown
- 2012-04-27 ES ES12777376T patent/ES2709654T3/es active Active
- 2012-04-27 WO PCT/US2012/035502 patent/WO2012149356A2/en not_active Ceased
- 2012-04-27 EP EP12777376.0A patent/EP2702078B1/en active Active
- 2012-04-27 EP EP18204488.3A patent/EP3508500A1/en active Pending
- 2012-04-27 AU AU2012249454A patent/AU2012249454B2/en active Active
- 2012-04-27 MX MX2013012572A patent/MX339239B/es active IP Right Grant
- 2012-04-27 KR KR1020137031244A patent/KR102037432B1/ko active Active
- 2012-04-27 JP JP2014508610A patent/JP6125489B2/ja active Active
- 2012-04-27 CN CN201610992824.0A patent/CN106928362B/zh active Active
-
2013
- 2013-10-27 IL IL229098A patent/IL229098A0/en unknown
- 2013-10-29 ZA ZA2013/08022A patent/ZA201308022B/en unknown
-
2014
- 2014-06-05 US US14/297,052 patent/US8957193B2/en active Active
-
2015
- 2015-02-03 US US14/613,110 patent/US9266956B2/en active Active
-
2016
- 2016-01-14 US US14/995,741 patent/US9556278B2/en active Active
- 2016-05-26 JP JP2016104893A patent/JP2016199552A/ja not_active Withdrawn
- 2016-12-19 US US15/384,003 patent/US11001637B2/en active Active
-
2018
- 2018-04-13 JP JP2018077514A patent/JP6807890B2/ja active Active
-
2021
- 2021-04-07 US US17/224,675 patent/US20220049005A1/en not_active Abandoned
-
2023
- 2023-02-16 US US18/170,244 patent/US20240158523A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG194701A1 (en) | Anti-cd40 antibodies and methods of use | |
| NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
| EP2614085A4 (en) | ANTI-IL-1 ANTIBODIES AND METHOD FOR THEIR USE | |
| MX2013009362A (es) | Anticuerpo contra el csf-1r. | |
| MX2013009679A (es) | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. | |
| TN2015000050A1 (en) | Methods of treating a tauopathy | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| CA3019531A1 (en) | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer | |
| MY195289A (en) | Anti IL-36R Antibodies | |
| PH12017500864A1 (en) | Anti-notch1 antibodies | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| TN2012000462A1 (en) | Anti-cd40 antibodies | |
| MX342240B (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
| TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
| EP4603508A3 (en) | Anti-frizzled antibodies and methods of use | |
| PH12014500841B1 (en) | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE | |
| MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
| MX2015017853A (es) | Anticuerpos contra el receptor 1 de ldl oxidada tipo lectina de metodos de uso. | |
| MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| MY187513A (en) | Lectin-like oxidized ldl receptor 1 antibodies and methods of use | |
| HK1216754A1 (zh) | 抗-rankl抗体及其使用方法 | |
| PH12013500432A1 (en) | Anti-vegfr-3 antibody compositions | |
| TN2013000068A1 (en) | Anti-vegfr-3 antibody compositions | |
| TN2013000265A1 (en) | Anti-cd38 antibodies |